

Disclosures

- I personally prepared this slide deck; it is without commercial bias or influence
- I have received financial reimbursement for non-marketed, non-branded, non-promotional educational presentations through the Abbott Nutrition Health Institute (ANHI)




Terry S. Johnson APN, NNP-BC, ASPPS

2


Objectives

- Define the term "dysbiosis"
- Describe two functions of human milk oligosaccharides (HMOs) in the neonatal gut
- Discuss the concept of a "dose-response" in relation to using human milk in the preterm infant's diet
- List three neonatal comorbidities that can be reduced with an exclusive human milk diet (EHMD)






Infant grows and develops






##Evolutionary Discordance" In last 60+ years the complexity of pregnancy, labor, delivery, and neonatal care have changed Advanced maternal age Assisted reproductive technology Multiple gestation pregnancy Premature delivery Antibiotic exposure Maternal morbidities Maternal diet Maternal obesity Environmental toxins Reference Than We Imagined








Dysbiosis: Inflammation and the Microbiome Origin of dysbiosis in preterm infants: Dysbiosis is characterized by: 37% of pregnant women receive antibiotics during pregnancy Low diversity in the microbiome Overall reduction in beneficial and/or commensal bacteria · 33% receive them in the intrapartum period Early or prolonged ROM; maternal stress


- Antenatal steroids \Rightarrow immune system
- 85% of all ELBW infants receive at least one course of broad-spectrum antibiotics
- ↑ Opportunistic pathogens of the gamma-proteobacteria class
- These factors interact to produce inflammation in the gut, which further perpetuates dysbiosis
- The potential for dysbiosis, limited capacity for localization, and the potential initiation of systemic inflammation


13





14


























Exclusive Human Milk Diet and Dose Response EHMD: multicenter retrospective cohort study Objective To compare clinical outcomes in 1587 extremely premature infants (birth weight <1250 g) before and after an institutional change to the use of an exclusive human milk diet (EHMD) including fortifiers from a diet that included cow milk-based (CMD) products (formulas and/or fortifiers) Method Conducted at four geographically disparate hospitals: Texas, California, Illinois, and Florida Each of the four hospitals reviewed charts from an equal period before and after implementing an exclusive human milk-based protocol





Exclusive Human Milk Diet and Dose Response

Bronchopulmonary Dysplasia (BPD)

- Reduction in BPD with EHMD
- 8.6% less BPD (Hair AB et al 2016) 9.0% less BPD (Assad M et al 2016)
- 16.5% less BPD (Delaney Manthe E et al 2019)
- 15.0% less BPD (Huston RK et al 2020)
- Role of Increased Use of Human Milk?
- Role of Earlier Enteral Feeding?
- Role of Earlier Fortification?



28

Human Milk: A Source of More Life Than We Imagined

Retinopathy of Prematurity (ROP)

- Reduction in ROP with EHMD
 - 3.8% less ROP (Hair AB et al 2016) Up to 26% less ROP (Assad M et al 2016)
- 8.6% less ROP (O'Connor et al et al 2018)
- 13.5% less ROP (Delaney Manthe E et al 2019)
- Role of Increased Use of Human Milk? Role of Earlier Enteral Feeding?



29

Human Milk: A Source of More Life Than We Imagined


Late-Onset Sepsis (LOS)


- Reduction in LOS with EHMD
 - For every 10% ↑ CMBD 17.9% ↑ LOS 11.3% reduction in LOS (Hair AB et al 2016)
 - 10.5% reduction in LOS (O'Connor et al 2018) 12.5% less sepsis evals (Delaney Manthe E et al 2019)
- Role of Increased Use of Human Milk?
- Role of Earlier Enteral Feeding?





Exclusive Human Milk Diet and Dose Response Implementation of an EHMD and Neonatal Comorbidities Goals Goals FilmD for infants <1250 gm Results: N = 205 infants; 101 CMB-HMF and 104 infants EHMD NEC rates not statistically relevant Surgical NEC declined from 4 cases (57%) to 1 case (14.3%) Significant decrease in number of LOS evaluations completed ROP declined from 62% to 48.5% (P = .054) BPD n EHMD group 48.5% in CMB-HMF 65% (P = .018) Growth not statistically different Financial audits showed products reimbursed at anticipated rate






Exclusive Human Milk Diet: Emerging Populations Congenital Gut Disorders (CGD) Study



- Gastroschisis, omphalocele, intestinal atresia
- Case-control, comparative effectiveness trial, (cohort, 2012-2015), n = 62/100-150
- >1250 g, >32 weeks EGA
- EHM with EHM fortification (Surgifort® fortifier and Prolact+ H²MF fortifier) following repair
- Time to full enteral feeds, days on TPN in neonates with CGD who receive an EHMD, vs those receiving partial and non-human milk diet
- Peak conjugated bilirubin, feeding tolerance/interruptions, sepsis, NEC, and death

34



35

